The entire information contained in this document and any other information in relation to GEMoaB and Cellex (jointly “Company”) and their affiliates, regardless of manner or form (“Information”), that is disclosed to the recipient (“Recipient“), is subject to the following provisions:
The Information remains the property of the Company, any copying, distribution, amendment and publication shall require the prior written consent of the Company. The Information may only be used by the Recipient for the purpose for which it has been provided by the Company to the Recipient.
The Company does not assume any liability whatsoever for potentially incomplete or incorrect statements contained in the Information. In particular, the Company does not assume any liability whatsoever for statements based on future events or other forward-looking statements. The Company assumes that potential partners will perform and rely on their own independent analyses as the case may be. The Company will be under no obligation to update the Information.
Under no circumstances does the Information or its delivery form any basis for a possible contract between the clients or their representatives and the Recipient.
GEMoaB Monoclonals GmbH
Phone: +49 351 4466 4500
Fax: +49 351 4466 450 99
Registergericht: Amtsgericht Dresden HRB 30429
Ust.-Id-Nr.: DE 279973627
Geschäftsführer: Prof. Dr. med. Gerhard Ehninger, Dr. Armin Ehninger, Michael Pehl, Volker Knöll